Skip to content
FDA Approves Inhaled Insulin
atti_editor posted:
"The FDA has approved inhaled insulin to treat type 1 and type 2 diabetes .The insulin, called Afrezza, is a rapid-acting insulin and is meant to be taken at mealtime or soon after."

"Afrezza carries a warning as it may cause a sudden tightening of the chest. It is not recommended for people with asthma or COPD . It is also not recommended for people that smoke or for the treatment of diabetic ketoacidosis."

Click on the link above for more information.

Will you be considering speaking with your doctor about this drug?
Was this Helpful?
1 of 1 found this helpful
nutrijoy responded:
Afrezza, the trademarked name of the inhaled insulin, has an interesting video available entitled, "Timing is Everything (just click on the link to view it)." In its clinical trials, the manufacturer (Mannkind Corporation) claimed that the inhaled insulin had a much faster onset of action than the fast-acting analogs (Novalog, Humalog and Apidra). My primary concern lies in the potential adverse effects the drug may have on lung tissue, particularly long term. The accuracy of dosing may be another potential problem as absorption of any inhaled medication could vary somewhat from one dose to another.

Afrezza already carries warnings that it should not be used by those patients suffering from asthma and COPD. Most people who have been diabetic for any extended period of time often wind up with beta cell dysfunction that deprives them of the ability to maintain basal insulin secretion. Many others lack the ability to produce, store, and secrete first phase prandial insulin and must rely almost exclusively on the much slower secretion of second phase insulin response. The latter, of course, results in post prandial spikes and surges because of the differences in timing between the insulin needed and food digested. Afrezza claims to address this weakness of injectable insulins.

Here's a warning (that may be sugar-coated) posted on the manufacturer's website:
"In clinical trials of up to two years duration in Type 1 and Type 2 adult patients with diabetes, observed changes in lung function were small, did not progress and resolved when AFREZZA treatment was discontinued. The most common respiratory side effect experienced with AFREZZA in trials was a mild, transient, non-productive cough. Discontinuation due to cough was uncommon."

Despite potential drawbacks, the inhaled insulin may provide doctors with a valuable tool for those diabetic patients who really need to supplement with insulin but have unfounded fears of needles which has been the deal-breaker in the past.

Another anti-diabetic drug that has failed to receive the attention that it deserves is an SGLT2-inhibitor marketed under the name of Invokana. This once-a-day medication works on the kidneys and essentially "tops off" serum glucose levels at the 140mg/L mark. Any serum glucose in excess of 140mg/L is kicked out of the system (excreted via the urine) and thus the medication can provide valuable protection against complications (because most complications become most damaging and progressive when blood glucose levels exceed the 140 mg/L tipping point).

Helpful Tips

Getting blood sugar under control using insulin
I normally like Dr. Gabe Mirkin 's advice and newsletters. But in one of his most recent newsletter articles, he commits the same medical ... More
Was this Helpful?
2 of 6 found this helpful

Expert Blog

Conquering Diabetes - Michael Dansinger, MD

Dr. Michael Dansinger provides thoughtful tips for those with type 2 diabetes or pre-diabetes who want to reclaim their health...Read More

Related Drug Reviews

  • Drug Name User Reviews

Report Problems With Your Medications to the FDA

FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.